- Home
- RERE vs TRDA Comparison
RERE vs TRDA Comparison
Compare RERE & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RERE
- TRDA
- Stock Information
- Founded
- RERE 2011
- TRDA 2016
- Country
- RERE China
- TRDA United States
- Employees
- RERE N/A
- TRDA N/A
- Industry
- RERE Other Specialty Stores
- TRDA Biotechnology: Pharmaceutical Preparations
- Sector
- RERE Consumer Discretionary
- TRDA Health Care
- Exchange
- RERE Nasdaq
- TRDA Nasdaq
- Market Cap
- RERE 527.7M
- TRDA 609.7M
- IPO Year
- RERE 2021
- TRDA 2021
- Fundamental
- Price
- RERE $2.40
- TRDA $17.85
- Analyst Decision
- RERE
- TRDA Strong Buy
- Analyst Count
- RERE 0
- TRDA 3
- Target Price
- RERE N/A
- TRDA $23.33
- AVG Volume (30 Days)
- RERE 602.7K
- TRDA 132.5K
- Earning Date
- RERE 11-20-2024
- TRDA 11-05-2024
- Dividend Yield
- RERE N/A
- TRDA N/A
- EPS Growth
- RERE N/A
- TRDA N/A
- EPS
- RERE N/A
- TRDA 1.55
- Revenue
- RERE $2,003,353,284.00
- TRDA $215,232,000.00
- Revenue This Year
- RERE $26.08
- TRDA $47.63
- Revenue Next Year
- RERE $25.55
- TRDA N/A
- P/E Ratio
- RERE N/A
- TRDA $11.51
- Revenue Growth
- RERE 28.24
- TRDA 146.92
- 52 Week Low
- RERE $1.01
- TRDA $10.75
- 52 Week High
- RERE $3.19
- TRDA $20.49
- Technical
- Relative Strength Index (RSI)
- RERE 43.95
- TRDA 48.42
- Support Level
- RERE $2.30
- TRDA $19.28
- Resistance Level
- RERE $2.63
- TRDA $20.49
- Average True Range (ATR)
- RERE 0.10
- TRDA 0.92
- MACD
- RERE -0.01
- TRDA -0.01
- Stochastic Oscillator
- RERE 26.76
- TRDA 25.21
About RERE ATRenew Inc.
ATRenew Inc is a pre-owned consumer electronics transactions and services platform in China. The majority of its revenue is derived from online product sales of phones and other consumer electronics goods through its platform. The Company's principal operations and geographic markets are in the People's Republic of China.
About TRDA Entrada Therapeutics Inc.
Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.